发布日期：2004 年 10 月
英文标题：N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.
作者：Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A.
出处：Circulation. 2004 Oct 12;110(15):2168-74.
内容介绍：心衰患者住院期间 NT-proBNP 变化趋势，反映患者预后。NT-proBNP 水平降幅 ≥ 30% 的患者远期不住院生存率优于其他患者，降低 ≥ 30%、改变<30%、升高 ≥ 30% 三组平均住院时间分别为：11.3、10.2、13.4 天。
摘要展示：
BACKGROUND:
Heart failure (HF) is responsible for a huge burden in hospital care. Our goal was to evaluate the value of N-terminal-pro-brain natriuretic peptide (NT-proBNP) in predicting death or hospital readmission after discharge of HF patients.
METHODS AND RESULTS:
We included 182 patients consecutively admitted to hospital because of decompensated HF. Patients were followed up for 6 months. The primary end point was death or readmission. Twenty-six patients died in hospital. The median admission NT-proBNP level was 6778.5 pg/mL, and the median level at discharge was 4137.0 pg/mL (P<0.001). Patients were classified into 3 groups: (1) decreasing NT-proBNP levels by at least 30% (n = 82), (2) no significant modifications on NT-proBNP levels (n = 49), and (3) increasing NT-proBNP levels by at least 30% (n = 25). The primary end point was observed in 42.9% patients. Variables associated with an increased hazard of death and/or hospital readmission in univariate analysis were length of hospitalization, heart rate, signs of volume overload, no use of ACE inhibitors, higher NYHA class at discharge, admission and discharge NT-proBNP, and the change in NT-proBNP levels. The variation in NT-proBNP was the strongest predictor of an adverse outcome. Independent variables associated with an increased risk of readmission or death were signs of volume overload and the change in NT-proBNP levels.
CONCLUSIONS:
Variations in NT-proBNP levels are related to hospital readmission and death within 6 months. NT-proBNP levels are potentially useful in the evaluation of treatment efficacy and might help clinicians in planning discharge of HF patients. Whether therapeutic strategies aimed to lower NT-proBNP levels modify prognosis warrants future investigation.
